1. Hydroxychloroquine in a G6PD-Deficient Patient with COVID-19 Complicated by Haemolytic Anaemia: Culprit or Innocent Bystander
- Author
-
Geraldine Claes, Sammy Place, François Mastroianni, Vincent Colombie, Axelle Gilles, and Frederic Vandergheynst
- Subjects
Pediatrics ,medicine.medical_specialty ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,lcsh:Medicine ,Context (language use) ,Culprit ,03 medical and health sciences ,0302 clinical medicine ,hemic and lymphatic diseases ,Internal Medicine ,medicine ,Bystander effect ,030212 general & internal medicine ,030203 arthritis & rheumatology ,Red blood cell disorders ,haemolytic anaemia ,business.industry ,lcsh:R ,Hydroxychloroquine ,Articles ,sars-cov-2 ,covid-19 ,g6pd deficiency ,business ,medicine.drug - Abstract
Hydroxychloroquine has been used worldwide as a first-line treatment for patients hospitalized with COVID-19. Little is known about COVID-19 and its effects on patients with congenital red blood cell disorders. We report a case of haemolytic anaemia in a 32-year-old patient and a fortuitous highlighting of G6PD deficiency. We reviewed the literature to assess the risk of hydroxychloroquine use in this context. LEARNING POINTS: A rapid drop in haemoglobin in COVID-19 patients should alert physicians to test for haemolytic anaemia and enzymopathies. Our review of the literature shows that use of hydroxychloroquine is safe in G6PD-deficient patients.
- Published
- 2020